| Home Market Dynamics You and Market Sector Analysis Company Insights AI Investing About Contact Us Login |
| The price action of Health Care (XLV) sector is shaped by numerous forces, ranging from broad macroeconomic trends to company-specific performance and market structure. The overall sentiment for Health Care sector is very positive (overall 3.4, positive 3.9, negative -0.5) on 20251120. The forces of Sentiment towards Fundamentals (2.3), Price Level (2), Valuation Sentiment (1.9), Option Speculation (1.5), and Broad Market Trend (-0.3) will drive up the price. The forces of Sector Price Trend (-0.7), and Market Risk Prefrence (0) will drive down the price. 'Buy the dips' is the preferred trading strategy. Hourly SMA 20 trend line is likely to provide a support from any pullbacks. The swing to upside will be significant considering the high positive sentiment forces (3.9). The extreme bullish overall sentiment (3.4) may signal the top of this uptrend. The sentiment for Broad Market Trend is calculated based on SPY trend. The sentiment for Sector Price Trend is calculated based on XLV trend. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Prefrence is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. |
| Date | Attention | Average Attention | Price | Price Level | Change | SMA10 Trend | Market Sentiment | Trend Sentiment | Fundamentals | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-20 | 2% | 1.6% | 151.38 | 75 | -0.62% | 0.4% | 2 | -0.2 | 2.3 | 6.3 |
| 2025-11-19 | 1% | 1.4% | 152.32 | 84 | -0.17% | 0.47% | 1.9 | 0.5 | 2.2 | 2.7 |
| 2025-11-18 | 2% | 1.4% | 152.58 | 90 | 0.56% | 0.47% | 2 | 1 | 1.8 | 2.3 |
| 2025-11-17 | 2% | 1.3% | 151.74 | 89 | -0.09% | 0.47% | 2.1 | 1.1 | 1.6 | 1.6 |
| 2025-11-16 | 0% | 1.1% | 2.9 | 1.5 | 2 | 5 | ||||
| 2025-11-15 | 1% | 1.1% | 3 | 1.5 | 2.1 | -6.5 | ||||
| 2025-11-14 | 3% | 1.1% | 151.87 | 96 | -0.59% | 0.54% | 2.9 | 1.5 | 2.2 | 1.2 |
| 2025-11-13 | 1% | 0.9% | 152.77 | 112 | -0.03% | 0.61% | 3.1 | 1.6 | 2.4 | -0.2 |
| 2025-11-12 | 1% | 1% | 152.81 | 126 | 1.4% | 0.55% | 3.5 | 1.6 | 2.2 | 2.2 |
| 2025-11-11 | 1% | 1.1% | 150.69 | 126 | 2.32% | 0.41% | 3.1 | 0.9 | 2.2 | 2.2 |
| Both emotion scores and sentiment scores are calculated in a -10 - +10 scale. | The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| 1 (8) Abbott To Acquire Exact Sciences For About $23 Billion Abbott Laboratories (ABT) on Thursday said it has agreed to acquire Exact Sciences (EXAS) in a transaction worth an enterprise value of about $23 billion. Under the terms of the agreement, Exact Sciences shareholders will receive $105 per share. (https://www.rttnews.com/) Thu. Nov 20, 2025 | |
| 2 (8) Solventum To Acquire Privately-held Acera Surgical For Up To $850 Mln Healthcare company Solventum Corp. (SOLV) announced Thursday it has entered into a definitive agreement to acquire Acera Surgical, a privately held bioscience company, for $725 million in cash plus up to $125 million in contingent cash payments based on the achievement of certain future milestones. (https://www.rttnews.com/) Thu. Nov 20, 2025 | |
| 3 (7) GE HealthCare To Buy Intelerad For $2.3 Bln GE HealthCare (GEHC) on Thursday said it has agreed to buy Intelerad, a medical imaging software provider for the healthcare industry, for a purchase price of $2. (https://www.rttnews.com/) Thu. Nov 20, 2025 | |
| 4 (8) GE HealthCare to Buy Intelerad for $2.3 Billion in Cash GE HealthCare Technologies Inc. is buying Intelerad Medical Systems Inc., a maker of medical imaging software, for $2.3 billion in cash to expand its efforts in cloud software and artificial intelligence. (https://www.bloomberg.com/) Thu. Nov 20, 2025 | |
| 5 (7) GE Healthcare to acquire Intelerad for $2.3 billion () -GE Healthcare said on Thursday it will acquire medical imaging software provider Intelerad for $2. (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Leroy Leo). (https://finance.yahoo.com/) Thu. Nov 20, 2025 | |
| 6 (8) Vanda Reports Big Win In Wegovy Support Study, Analysts Upbeat Vanda's tradipitant cut Wegovy-related vomiting by 50% in a new trial, prompting bullish analyst views and price targets. (https://www.benzinga.com/) Thu. Nov 20, 2025 | |
| 7 (3) Just Two Sectors Account for 100% of US Job Growth in 2025 If you’re looking for a job in health care or hospitality, the good news is US companies are hiring. But employers across the rest of the economy are scaling back. (https://www.bloomberg.com/) Thu. Nov 20, 2025 | |
| 8 (8) FDA Signs Off On Bayer's New Lung Cancer Drug — Early Results Look Promising FDA grants accelerated approval to Bayer's Hyrnuo and full approval to Amgen's Imdelltra, expanding treatment options for advanced lung cancer. (https://www.benzinga.com/) Thu. Nov 20, 2025 | |
| 9 (5) Why Abbott is paying $21 billion for Exact Sciences and its Cologuard cancer test Abbott is getting into the cancer-testing game with its $21 billion acquisition of Cologuard test maker Exact Sciences. (https://www.marketwatch.com/) Thu. Nov 20, 2025 | |
| 10 (7) Abbott’s $21 Billion Exact Sciences Deal Fills Void Of Lost Covid Test Sales Abbott Laboratories $21 billion deal to acquire cancer test maker Exact Sciences could bolster the company’s diagnostic division that has lost sales from COVID tests. (https://www.forbes.com/) Thu. Nov 20, 2025 | |
| 11 (8) Abbott's $21 Billion Exact Sciences Buyout Reshapes Cancer Diagnostics Abbott will acquire Exact Sciences for $21 billion, adding Cologuard and expanding its diagnostics portfolio as analysts highlight growth and valuation momentum. (https://www.benzinga.com/) Thu. Nov 20, 2025 | |
| 12 (8) FDA Approval Delivers Momentum For AstraZeneca's Rare Disease Portfolio AstraZeneca receives FDA approval for Koselugo to treat adults with NF1 and inoperable plexiform neurofibromas, backed by strong Phase 3 data. (https://www.benzinga.com/) Thu. Nov 20, 2025 | |
| 13 (7) Abbott to Buy Cancer-Screener Exact Sciences for $21 Billion Abbott Laboratories agreed to acquire cancer-screening company Exact Sciences Corp., in a deal with a total equity value of about $21 billion. (https://www.bloomberg.com/) Thu. Nov 20, 2025 | |
| 14 (8) Abbott bolsters diagnostics portfolio with up to $23 billion buyout of Exact Sciences Abbott said on Thursday it would buy cancer test maker Exact Sciences in an up to $23 billion deal, bolstering the medical device maker's diagnostics business. (https://www.cnbc.com/) Thu. Nov 20, 2025 | |
| 15 (7) Why Abbott is paying $21 billion for Exact Sciences and its Cologuard cancer test Abbott is getting into the cancer-testing game with its $21 billion acquisition of Cologuard test maker Exact Sciences. (https://www.marketwatch.com/) Thu. Nov 20, 2025 | |
| 16 (-6) 133-year-old big pharma company plans layoffs, files WARN notice The global drugmaker is laying off workers as part of a restructuring. (https://www.thestreet.com/) Thu. Nov 20, 2025 | |
| 17 (7) Nanox To Acquire VasoHealthcare IT To Boost U.S. AI Imaging Expansion Nano-X Imaging Ltd. (NNOX) announced on Wednesday that it has agreed to acquire VasoHealthcare IT Inc. from Vaso Corporation (VASO), a move aimed at accelerating the rollout of its AI-driven medical imaging solutions across U. (https://www.rttnews.com/) Wed. Nov 19, 2025 | |
| 18 (8) Abbott Nears Deal for Cancer Test Maker Exact Sciences Abbott Laboratories is nearing a potential acquisition of medical-testing company Exact Sciences Corp., in what would be its largest deal in nearly a decade, people familiar with the matter said. (https://www.bloomberg.com/) Wed. Nov 19, 2025 | |
| 19 (0) 10 Health Care Stocks With Whale Alerts In Today's Session (https://www.benzinga.com/) Wed. Nov 19, 2025 | |
| 20 (-6) Opinion: UnitedHealth is dropping a million seniors from Medicare Advantage as it aims to restore its ‘swagger’ America’s largest insurer is making sweeping changes to its Medicare Advantage plans to improve profit margins. (https://www.marketwatch.com/) Wed. Nov 19, 2025 | |
| 21 (7) HCA Healthcare Is a Safe Port in a Storm As the market rotation continues, less focus on technology and more on healthcare. (https://www.thestreet.com/) Wed. Nov 19, 2025 | |
| 22 (0) Eli Lilly Unusual Options Activity For November 19 (https://www.benzinga.com/) Wed. Nov 19, 2025 | |
| 23 (6) Healthcare Rotation Underway: 3 Stocks Leading the Charge Market Analysis by covering: Eli Lilly and Company, Merck & Company Inc, NVIDIA Corporation, S&P 500. Read 's Market Analysis on Investing.com (https://www.investing.com/) Wed. Nov 19, 2025 | |
| 24 (-6) Opinion: UnitedHealth is dropping a million seniors from Medicare Advantage as it aims to restore its ‘swagger’ America’s largest insurer is making sweeping changes to its Medicare Advantage plans to improve profit margins. (https://www.marketwatch.com/) Wed. Nov 19, 2025 | |
| 25 (8) This former Eli Lilly exec just raised a $52 million seed round from family offices to build a new healthcare AI startup Thirty Madison's former president is launching her own healthcare AI startup without a drop of VC funding. (https://www.businessinsider.com/) Wed. Nov 19, 2025 | |
About
Contact Us
Copyright ©2025 TheMarketUnfolds. All rights reserved. Denver, Colorado, USA